Roivant Sciences Ltd. (ROIV)
Nasdaq · Common stock · Pharmaceutical Preparations
As of Oct 21, 2:16 PM ET15 min delayedAbout 15 minutes behind the market. Every member plan is real time.
Follow ROIV in real time
Real-time quotes, Pro Charting, the scanner and the alert feed on ROIV and every other US listing.
Start 5 days freeTry Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
ROIV at a glance
Key statistics
$25.22B
Market capitalization
- Previous close
- $34.92
- Open
- $38.48
- Day range
- $36.17 – $38.48
- Volume
- 10.94M
- Average volume (30 sessions)
- 7.01M
- Shares outstanding
- 722.32M
- Earnings per share
- $(0.37)
- Price / book
- 6.0
- Price / sales
- 3348.8
- Beta (1 year, vs SPY)
- 1.04
Where the price sits in its year
52-week range
76% of the range
- Below the 52-week high
- -14.2%
- Above the 52-week low
- +111.0%
Completed sessions through Oct 20, 2026
Technical snapshot
Below its 50-day average, above its 200-day
- 20-day average
- $35.22-0.9%
- 50-day average
- $36.58-4.5%
- 200-day average
- $30.92+12.9%
Between the conventional 30 and 70 bands.
+4.7%
1 week
-10.4%
1 month
+0.0%
3 months
+60.9%
Year to date
+102.3%
1 year
Price change over each window, from completed sessions. Past performance does not indicate future results.
Every plan: MACD, ATR, the 20- and 50-day ranges, five-year and all-history extremes and the full indicator set, live on Pro Charting.The member platform, in real time
What members do with ROIV
ROIV on Pro Charting
Every intraday interval in real time, the drawing kit and the full set of technical studies on ROIV.
See the plans →
Every planScreen names like ROIV
The real-time scanner: price, volume, technical, fundamental and chart-pattern filters across the whole US market.
See the plans →
Analysis Tools OnlySet a price line on ROIV
Put ROIV on your watchlist, draw the levels you care about, and My Dashboard tracks where it trades against them.
See the plans →
Stock Alerts + ToolsOpen alerts on ROIV
See whether there is an open premium alert on ROIV, with its entry, stop and exit, each one reviewed by an analyst before it is sent.
See the plans →
From the public news wire
ROIV headlines
- Roivant and Priovant Announce Positive Results in CLARITY-1 and CLARITY-2 Phase 3 Trials for Brepocitinib in Non-Infectious Uveitis (NIU)
GlobeNewswire Inc. · Oct 21, 2026
- Roivant and Priovant Announce Positive Phase 3 VALOR Study Results for Brepocitinib in 52-Week Placebo-Controlled Trial in Dermatomyositis (DM)
GlobeNewswire Inc. · Sep 17, 2025
- Roivant Sciences Offloads Psoriasis Medicine Maker To Organon For Up To $1.2B
Benzinga · Sep 18, 2024
- Roivant Sciences Unveils New 'Vant' Subsidiary For In-Licensed Pulmonary Hypertension Drug From Bayer
Benzinga · Sep 10, 2024
- The Analyst Verdict: Roivant Sciences In The Eyes Of 6 Experts
Benzinga · May 31, 2024
- Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business Update
GlobeNewswire Inc. · May 30, 2024
- Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provide Business Update on Thursday, May 30, 2024
GlobeNewswire Inc. · May 16, 2024
- Critical Insights From Roivant Sciences Analyst Ratings: What You Need To Know
Benzinga · Apr 22, 2024
SEC Form 4, most recent first
Insider filings
Sukhatme Mayukh
−20.0K
President & CIO, Director · Shares withheld for tax
$669.80K · Oct 16, 2026
Gline Matthew
−34.6K
CEO, Director · Shares withheld for tax
$1.16M · Oct 16, 2026
Epperly Melissa B,
−900
Director · Open-market sale
$32.91K · Oct 1, 2026
Epperly Melissa B,
−17.8K
Director · Option exercise
· Oct 1, 2026
Epperly Melissa B,
−16.9K
Director · Open-market sale
$607.95K · Oct 1, 2026
Epperly Melissa B,
+17.8K
Director · Option exercise
$79.17K · Oct 1, 2026
Venker Eric
−200.0K
President & Immunovant CEO · Option exercise
· Sep 30, 2026
Torti Frank
+40.3K
President and Vant Chair · Shares withheld for tax
$1.47M · Sep 30, 2026
About Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
- Exchange
- Nasdaq
- Security
- Common stock
- Industry
- Pharmaceutical Preparations
- Headquarters
- London
- Employees
- 721
- Listed since
- Oct 1, 2021
- Website
- roivant.com
Pick the desk that fits how you trade
Analysis Tools Only for the real-time scanner, Pro Charting and the research desk. Stock Alerts + Tools for the human-reviewed alert feed. Premium Membership for both, at one price.
Try Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
Other plans from $39 a month. Pay by card, Apple Pay, Google Pay, Link, Cash App Pay or Amazon Pay through Stripe.